Trump Finalizes Better-Than-Feared Medicare Advantage Rate — Health Insurers Surge

The Rollercoaster Ride From "Flat" to Relief

Imagine you're an investor. It's late January. You've just poured your morning coffee, and then ,  bam , the CMS drops a bombshell.

Medicare Advantage payment rates for 2027? They're proposing a 0.09% increase.

That's basically nothing. Less than nothing when you factor in rising medical costs. Wall Street had been expecting 4% to 6%. The gap was so massive that health insurers collectively lost nearly $90 billion in market value overnight. UnitedHealth and Humana plunged. Analysts called it a "shock to the system."

Fast forward to April 6, 2026. The Trump administration does something unexpected. It finalizes a 2.48% average rate increase for 2027 , dramatically higher than the near-flat January proposal. Insurance stocks surge 8% to 14% in extended trading. Humana jumps 11%. CVS rises 8%. Elevance climbs 7%.

Relief, right?

Well... mostly. But there's a catch. And it's a big one.

Let's break down what just happened, who wins, and why the headline numbers don't tell the whole story.

---

By the Numbers: What CMS Actually Finalized

Let's get the math straight, because there's some confusion floating around.

2.48% , The Magic Number

On April 6, 2026, the Centers for Medicare & Medicaid Services (CMS) finalized an average rate increase of 2.48% in payments to private insurers offering Medicare Advantage plans to older adults in 2027.

That translates to more than $13 billion in additional payments flowing to Medicare Advantage plans next year.

The 2026 rate (for the current year) was even larger , a 5.06% increase finalized last April, up from the Biden administration's original 2.2% proposal. That's over $25 billion in extra payments.

From 0.09% to 2.48%: How We Got Here

Here's where the drama lives.

The January proposal was so lean that analysts described it as "basically nothing" compared to expectations. The April reversal gave insurers precisely what they'd been lobbying for , a meaningful improvement that acknowledged the reality of rising medical costs.

Side note: This isn't the first time CMS has walked back an initial proposal. Last year, the agency more than doubled its initial rate before finalization. History repeats, and insurers know it.

---

The Winners: Which Insurers Benefit Most

Not all insurers are created equal when it comes to Medicare Advantage exposure. The rate hike lands differently depending on how concentrated a company's business is in MA.

Humana , Ground Zero for the Rate Relief

Humana is the most exposed of the major players. Medicare Advantage accounts for the vast majority of its revenue. That concentration cut both ways: when the January proposal dropped, Humana cratered. When the April reversal came, Humana soared , up 11% to $203.30 in after-hours trading.

Some analysts had warned that the flat proposal could trigger a potential 20% earnings hit for insurers heavily reliant on MA. The reversal effectively averted that disaster.

UnitedHealth, CVS, and Elevance Join the Rally

UnitedHealth and CVS have broader business lines that can buffer Medicare Advantage volatility , think Optum for UnitedHealth, pharmacy and PBM operations for CVS. Humana doesn't have that luxury.

Still, all three gained:

• Humana: 11% ↑
• CVS Health: 8% ↑ (to $78.81)
• Elevance Health: 7% ↑ (to $324)

UnitedHealth shares also rallied sharply, though the company faces additional headwinds including a DOJ probe into its billing practices and PBM reform legislation.

Quick reflection: This is a classic "rising tide lifts all boats" moment , but some boats have bigger holes than others.

---

But Wait , There's a Catch: The Structural Headwind

Here's the part that's getting lost in the excitement.

The Chart Review Crackdown Explained

The 2.48% rate hike sounds great. But CMS simultaneously finalized a change that could offset nearly the entire increase.

Starting in 2027, CMS will exclude diagnoses reported only through "unlinked" chart review records from risk-score calculations. In plain English? Insurers have long used retrospective medical record reviews to identify additional diagnoses that make patients appear sicker , and therefore generate higher payments. The government is now closing that loophole.

This change is projected to reduce average payments by 2.54% when accounting for underlying risk score trends.

Do the math: 2.48% increase minus 2.54% offset equals... essentially zero net benefit for the sector as a whole.

Why 2.48% Might Not Be All It Seems

The rule represents a permanent recalibration of the risk-adjustment model , away from documentation intensity and toward encounter-based clinical data. That shift will pressure margins for plans that historically relied on chart review strategies.

One analyst called the rate hike "a conviction buy on immediate liquidity" but warned that "the quality factor for the sector remains under scrutiny."

In other words: yes, the immediate relief is real. But don't mistake a one-time reprieve for a structural turnaround.

---

What This Means for Medicare Beneficiaries

You might be reading this and thinking: Okay, but I'm not an investor. I'm a Medicare beneficiary. What does this mean for me?

Fair question.

Will Seniors See Changes to Their Plans?

The January proposal was so lean that Fitch Ratings warned it would lead to "higher premiums, reduced benefits, and less coverage options" as insurers scaled back.

The April reversal dials back that risk , but doesn't eliminate it entirely. Even with the 2.48% increase, insurers face:

• Rising medical costs that outpace rate growth
• The chart review offset discussed above
• Continued regulatory pressure on prior authorization

Elevance's CEO put it bluntly in January: if funding consistently lags reality on the ground, the levers insurers can pull are "benefits, networks, premiums, exiting geographies." And, she added, "quite frankly, that's not good for seniors."

The Enrollment Picture: Slower Growth, Shifting Dynamics

Medicare Advantage enrollment reached 35.4 million beneficiaries in 2026 , but growth has slowed significantly. Year-over-year enrollment rose just 2.5%, down from 3.6% in 2025 and 3.9% in 2024.

Seven states actually saw MA enrollment decline for the first time. Insurers are pulling back from certain markets and reducing benefit richness.

The takeaway: The rate relief helps. But the days of double-digit MA growth and generous supplemental benefits for everyone? Those may be behind us.

---

What's Next for Medicare Advantage Rates

The 2027 Proposal Looms

Here's the twist that keeps healthcare investors up at night.

While CMS was finalizing the 2.48% rate for 2027, the administration also released its Advance Notice for 2028 , proposing a net average payment increase of just 0.09%. Again.

Analysts had expected 4% to 6%. The reaction was immediate and brutal.

The question hanging over the entire sector: Will CMS walk back the 2028 proposal the same way it walked back the 2027 proposal?

The industry is betting yes. But the politics around Medicare Advantage are shifting. Overpayments to MA plans are projected to reach $76 billion this year , payments in excess of what it would cost to cover the same beneficiaries in traditional Medicare.

At some point, the math becomes impossible to ignore.

The Trump administration just handed health insurers a meaningful win. The 2.48% Medicare Advantage payment hike for 2027 is a dramatic improvement over the near-flat January proposal, and the market responded accordingly , with billions in shareholder value restored.

But here's what savvy investors and industry watchers need to understand: the rate hike is a reprieve, not a reset.

Structural headwinds , including the chart review crackdown, slowing enrollment growth, and persistent political pressure on MA overpayments , remain firmly in place. The 2.48% increase looks generous until you net out the 2.54% risk adjustment offset.

So where does that leave us?

For investors: The rally reflects genuine relief. But overweighting MA-exposed names ignores the structural story. Diversification matters.

For insurers: The rate helps. But the business model is under pressure. The era of easy MA profits is ending.

For beneficiaries: Your plans probably won't change dramatically , for now. But watch the 2028 rate decision closely. That's where the real test lies.

---

Got questions about how Medicare Advantage rates affect your portfolio or your healthcare planning? Drop a comment below. And if you found this breakdown helpful, share it with someone who's trying to make sense of the healthcare regulatory maze.